Your browser doesn't support javascript.
loading
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.
Rahman, Rifaquat; Polley, Mei-Yin C; Alder, Laura; Brastianos, Priscilla K; Anders, Carey K; Tawbi, Hussein A; Mehta, Minesh; Wen, Patrick Y; Geyer, Susan; de Groot, John; Zadeh, Gelareh; Piantadosi, Steven; Galanis, Evanthia; Khasraw, Mustafa.
Afiliación
  • Rahman R; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: rrahman@bwh.harvard.edu.
  • Polley MC; Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.
  • Alder L; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Brastianos PK; Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Anders CK; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Tawbi HA; MD Anderson Cancer Center, Houston, TX, USA.
  • Mehta M; Miami Cancer Institute, Baptist Hospital, Miami, FL, USA.
  • Wen PY; Centre for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Geyer S; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • de Groot J; University of California San Francisco Brain Tumor Center, San Francisco, CA, USA.
  • Zadeh G; Department of Neurological Surgery University of Toronto, Toronto, ON, Canada.
  • Piantadosi S; Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Galanis E; Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.
  • Khasraw M; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Lancet Oncol ; 24(4): e161-e171, 2023 04.
Article en En | MEDLINE | ID: mdl-36990614
Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series of presentations at the First Central Nervous System Clinical Trials Conference hosted by the American Society of Clinical Oncology and the Society for Neuro-Oncology, we provide an overview on drug development and novel trial designs in neuro-oncology. This Review discusses the challenges of therapeutic development in neuro-oncology and proposes strategies to improve the drug discovery process by enriching the pipeline of promising therapies, optimising trial design, incorporating biomarkers, using external data, and maximising efficacy and reproducibility of clinical trials.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article